Ingenuity meets passion
Health Data Specialists, “Heads” is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with particular expertise in hemato-oncology studies. We provide the complete range of clinical trial services, from start-up to completion, from Phase I to IV. In addition, we provide strategic oncology drug development consulting and expert advice as we understand the challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market.
Heads has invested considerably in its infrastructure. We strive to employ top professionals and develop premier software to meet and exceed our client needs. At Heads we believe that true passion and devotion are key to be able to excel in what you do.
OUR CLINICAL RESEARCH
We invest heavily in our people and in-house technology. This way we can guarantee true ﬂexibility, customization and quality in our work.
Hemato-Oncology is the core of our global clinical program. As such, disease area expertise across all functions is a top priority.
Our engineers and quantitative scientists will back any decision making with concrete data. No leap of faith required!
We help organizations across the private, public, and social sectors create the change that matters. We have always helped our clients identify and set the direction toward their most important goals. Today, we go further: working together to turn these ambitious goals into reality.
A Phase 1/2 study of belantamab mafodotin administered in combination with daratumumab, lenalidomide and dexamethasone in patients with newly diagnosed MM not eligible for ASCT.
A Phase 1/2 study of belantamab mafodotin administered in combination with daratumumab, pomalidomide, and dexamethasone in relapsed/refractory MM patients treated with one line of therapy who are lenalidomide refractory.
A Phase 1/2 study of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat in naïve transplant ineligible MM patients.
A phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with NDMM as Maintenance Therapy Following ASCT
A Phase 3 pivotal study comparing daratumumab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone in relapsed refractory MM patients.
A Phase 3 study of Isatuximab in combination with carfilzomib, lenalidomide and dexamethasone (KRd) vs KRd alone in treatment naïve MM patients eligible for ASCT.
A retrospective study on the management and outcomes of 4500 patients with Systemic Light Chain Amyloidosis across Europe.
A Phase 1/2 study of belantamab mafodotin in combination with lenalidomide and dexamethasone in treatment naïve MM patients not eligible for ASCT.
A Phase 2 multi-centre study of isatuximab, bortezomib, cyclophoshamide and dexamethasone, followed by isatuximab-lenalidomide maintenace in treatment naïve MM patients with severe renal impairment.
A Phase 2 multi-centre study of isatuximab in combination with pomalidomide and dexamethasone in 1st relapse lenalidomide and proteasome inhibitor exposed MM patients.
A Phase 2 multi-centre study of belantamab mafodotin in relapsed refractory AL-Amyloidosis patients.
A Phase 2 multi-centre study of daratumumab monotherapy in newly diagnosed patients with Stage 3B light chain (AL) amyloidosis.
A Phase 2 multi-centre study of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone in MM patients with extramedullary disease.